Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Ganly

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
The New Zealand Medical Journal|December 8, 2006
Treatment with intravenous immunoglobulin is not a panacea but should be limited to those who can benefitPeter Ganly, Ruth Spearing
Leukemia & Lymphoma|April 6, 2004
Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemiaPeter Ganly, Logan C Walker, Christine M Morris
American Journal of Hematology|August 23, 2006
Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia veraPeter Ganly, Vickie Hanrahan, Bart Baker, et al.
Cancer Genetics and Cytogenetics|March 24, 2004
Constitutional t(5;7)(q11;p15) rearranged to acquire monosomy 7q and trisomy 1q in a patient with myelodysplastic syndrome transforming to acute myelocytic leukemiaPeter Ganly, Margaret McDonald, Ruth Spearing, et al.
Lancet (London, England)|December 17, 2008
Not walking or communicating--is all well?Peter Ganly, Mohamed Saleem, Helen Marr, et al.
Leukemia & Lymphoma|June 3, 2014
Development of T-cell lymphomas with an activated cytotoxic immunophenotype, including anaplastic large cell lymphomas, in patients with chronic lymphocytic leukemia: a series of six casesSarah Mant, Graeme Taylor, David Dutton, et al.
Current Medical Research and Opinion|July 16, 2009
Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemiaEnrique Hernandez, Peter Ganly, Veena Charu, et al.
Cancer Genetics and Cytogenetics|February 24, 2006
Translocation (5;10)(q22;q24) in a case of acute lymphoblastic leukemiaSheryl M Gough, Suzanne M Benjes, Margaret McDonald, et al.
The New Zealand Medical Journal|May 19, 2009
Successful treatment of transplant-associated microangiopathy with rituximabHelen Marr, Emma-Jane McDonald, Eileen Merriman, et al.
Internal Medicine Journal|November 10, 2018
Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centreBarry D Hock, Katie S Mulholland, Peter Ganly, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
The New Zealand Medical Journal|December 8, 2006
Treatment with intravenous immunoglobulin is not a panacea but should be limited to those who can benefitPeter Ganly, Ruth Spearing
Leukemia & Lymphoma|April 6, 2004
Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemiaPeter Ganly, Logan C Walker, Christine M Morris
American Journal of Hematology|August 23, 2006
Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia veraPeter Ganly, Vickie Hanrahan, Bart Baker, et al.
Cancer Genetics and Cytogenetics|March 24, 2004
Constitutional t(5;7)(q11;p15) rearranged to acquire monosomy 7q and trisomy 1q in a patient with myelodysplastic syndrome transforming to acute myelocytic leukemiaPeter Ganly, Margaret McDonald, Ruth Spearing, et al.
Lancet (London, England)|December 17, 2008
Not walking or communicating--is all well?Peter Ganly, Mohamed Saleem, Helen Marr, et al.
Leukemia & Lymphoma|June 3, 2014
Development of T-cell lymphomas with an activated cytotoxic immunophenotype, including anaplastic large cell lymphomas, in patients with chronic lymphocytic leukemia: a series of six casesSarah Mant, Graeme Taylor, David Dutton, et al.
Current Medical Research and Opinion|July 16, 2009
Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemiaEnrique Hernandez, Peter Ganly, Veena Charu, et al.
Cancer Genetics and Cytogenetics|February 24, 2006
Translocation (5;10)(q22;q24) in a case of acute lymphoblastic leukemiaSheryl M Gough, Suzanne M Benjes, Margaret McDonald, et al.
The New Zealand Medical Journal|May 19, 2009
Successful treatment of transplant-associated microangiopathy with rituximabHelen Marr, Emma-Jane McDonald, Eileen Merriman, et al.
Internal Medicine Journal|November 10, 2018
Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centreBarry D Hock, Katie S Mulholland, Peter Ganly, et al.
Pageof 3